Bioheart (02185.HK) announces clinical result for Iberis-HTN at CIT 2023

By /

Bioheart, together with its holding subsidiary Angiocare announces the clinical result for Iberis-HTN at China Interventional Therapeutics 2023.

Scroll to Top